source
- Boulevard Bio launches with $65 million to develop bispecific antibodies for IgA nephropathy and other autoimmune diseasesBoulevard Bio, a new biotech co-founded by autoimmune researcher Georg Schett and former Sanofi CSO Frank Nestle, announced its launch on Wednesday with $65 million in funding. The company’s first…
- Former Legend Biotech chief Ying Huang named CEO of K2, targets $250 million Series A to license Asian assetsYing Huang spent the past seven years building one of the leading cancer cell‑therapy companies before stepping down as CEO of Legend Biotech. Weeks after announcing his departure, Huang has taken…